423 related articles for article (PubMed ID: 12193095)
1. Endothelin stimulates an endogenous nitric oxide synthase inhibitor, asymmetric dimethylarginine, in experimental heart failure.
Ohnishi M; Wada A; Tsutamoto T; Fujii M; Matsumoto T; Yamamoto T; Takayama T; Wang X; Kinoshita M
Clin Sci (Lond); 2002 Aug; 103 Suppl 48():241S-244S. PubMed ID: 12193095
[TBL] [Abstract][Full Text] [Related]
2. Elevation of an endogenous inhibitor of nitric oxide synthesis in experimental congestive heart failure.
Feng Q; Lu X; Fortin AJ; Pettersson A; Hedner T; Kline RL; Arnold JM
Cardiovasc Res; 1998 Mar; 37(3):667-75. PubMed ID: 9659450
[TBL] [Abstract][Full Text] [Related]
3. Cardiovascular effects of systemic nitric oxide synthase inhibition with asymmetrical dimethylarginine in humans.
Kielstein JT; Impraim B; Simmel S; Bode-Böger SM; Tsikas D; Frölich JC; Hoeper MM; Haller H; Fliser D
Circulation; 2004 Jan; 109(2):172-7. PubMed ID: 14662708
[TBL] [Abstract][Full Text] [Related]
4. Effects of a specific endothelin-converting enzyme inhibitor on cardiac, renal, and neurohumoral functions in congestive heart failure: comparison of effects with those of endothelin A receptor antagonism.
Wada A; Tsutamoto T; Ohnishi M; Sawaki M; Fukai D; Maeda Y; Kinoshita M
Circulation; 1999 Feb; 99(4):570-7. PubMed ID: 9927406
[TBL] [Abstract][Full Text] [Related]
5. Role of ET(A) receptors in the regulation of vascular reactivity in rats with congestive heart failure.
Thorin E; Lucas M; Cernacek P; Dupuis J
Am J Physiol Heart Circ Physiol; 2000 Aug; 279(2):H844-51. PubMed ID: 10924085
[TBL] [Abstract][Full Text] [Related]
6. Chronic therapy with an ET(A/B) receptor antagonist in conscious dogs during progression of congestive heart failure. Intracellular Ca(2+) regulation and nitric oxide mediated coronary relaxation.
Shen YT; Buie PS; Lynch JJ; Krause SM; Ma XL
Cardiovasc Res; 2000 Nov; 48(2):332-45. PubMed ID: 11054479
[TBL] [Abstract][Full Text] [Related]
7. Chronic administration of phosphodiesterase type 5 inhibitor suppresses renal production of endothelin-1 in dogs with congestive heart failure.
Yamamoto T; Wada A; Ohnishi M; Tsutamoto T; Fujii M; Matsumoto T; Takayama T; Wang X; Kurokawa K; Kinoshita M
Clin Sci (Lond); 2002 Aug; 103 Suppl 48():258S-262S. PubMed ID: 12193099
[TBL] [Abstract][Full Text] [Related]
8. High plasma level of asymmetric dimethylarginine in patients with acutely exacerbated congestive heart failure: role in reduction of plasma nitric oxide level.
Saitoh M; Osanai T; Kamada T; Matsunaga T; Ishizaka H; Hanada H; Okumura K
Heart Vessels; 2003 Sep; 18(4):177-82. PubMed ID: 14520484
[TBL] [Abstract][Full Text] [Related]
9. Endothelin receptor antagonists in congestive heart failure: a new therapeutic principle for the future?
Spieker LE; Noll G; Ruschitzka FT; Lüscher TF
J Am Coll Cardiol; 2001 May; 37(6):1493-505. PubMed ID: 11345356
[TBL] [Abstract][Full Text] [Related]
10. Association of asymmetric dimethylarginine and endothelial dysfunction.
Böger RH
Clin Chem Lab Med; 2003 Nov; 41(11):1467-72. PubMed ID: 14656027
[TBL] [Abstract][Full Text] [Related]
11. The functional shift of endothelin receptor subtypes in dogs with heart failure produced by rapid ventricular pacing.
Tadano K; Hosokawa A; Fukuroda T; Nishikibe M
J Cardiovasc Pharmacol; 2004 Nov; 44 Suppl 1():S350-3. PubMed ID: 15838318
[TBL] [Abstract][Full Text] [Related]
12. Plasma concentration of asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, is elevated in monkeys with hyperhomocyst(e)inemia or hypercholesterolemia.
Böger RH; Bode-Böger SM; Sydow K; Heistad DD; Lentz SR
Arterioscler Thromb Vasc Biol; 2000 Jun; 20(6):1557-64. PubMed ID: 10845872
[TBL] [Abstract][Full Text] [Related]
13. Beneficial effects of long-term selective endothelin type A receptor blockade in canine experimental heart failure.
Moe GW; Albernaz A; Naik GO; Kirchengast M; Stewart DJ
Cardiovasc Res; 1998 Sep; 39(3):571-9. PubMed ID: 9861299
[TBL] [Abstract][Full Text] [Related]
14. Pathophysiological roles of endogenous endothelin-1 in dogs with chronic heart failure produced by rapid right ventricular pacing.
Tadano K; Suzuki J; Hanada K; Nakao M; Nakao R; Uehara S; Ohta H; Miyauchi T; Nishikibe M
J Pharmacol Exp Ther; 2001 Aug; 298(2):729-36. PubMed ID: 11454937
[TBL] [Abstract][Full Text] [Related]
15. Chronic endothelin blockade in dogs with pacing-induced heart failure: possible modulation of sympathoexcitation.
McConnell PI; Olson CE; Patel KP; Blank DU; Olivari MT; Gallagher KP; Quenby-Brown E; Zucker IH
J Card Fail; 2000 Mar; 6(1):56-65. PubMed ID: 10746820
[TBL] [Abstract][Full Text] [Related]
16. Asymmetric dimethylarginine endogenous inhibition of nitric oxide synthase causes differential vasculature effects.
Cable DG; Celotto AC; Evora PR; Schaff HV
Med Sci Monit; 2009 Sep; 15(9):BR248-53. PubMed ID: 19721392
[TBL] [Abstract][Full Text] [Related]
17. Increased endogenous nitric oxide synthase inhibitor in patients with congestive heart failure.
Usui M; Matsuoka H; Miyazaki H; Ueda S; Okuda S; Imaizumi T
Life Sci; 1998; 62(26):2425-30. PubMed ID: 9651109
[TBL] [Abstract][Full Text] [Related]
18. Chronic effects of a novel, orally active endothelin receptor antagonist, T-0201, in dogs with congestive heart failure.
Ohnishi M; Wada A; Tsutamoto T; Fukai D; Sawaki M; Maeda Y; Kinoshita M
J Cardiovasc Pharmacol; 1998; 31 Suppl 1():S236-8. PubMed ID: 9595447
[TBL] [Abstract][Full Text] [Related]
19. Asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, in maternal and fetal circulation.
Maeda T; Yoshimura T; Okamura H
J Soc Gynecol Investig; 2003 Jan; 10(1):2-4. PubMed ID: 12517586
[TBL] [Abstract][Full Text] [Related]
20. Acute effects of an endothelin-1 receptor antagonist bosentan at different stages of heart failure in conscious dogs.
Choussat R; Hittinger L; Barbe F; Maistre G; Carayon A; Crozatier B; Su J
Cardiovasc Res; 1998 Sep; 39(3):580-8. PubMed ID: 9861300
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
